55 - Late Breaker Abstracts: COVID-19 Treatment & Prophylaxis

Moderator(s)

• 

  Adarsh Bhimraj, MD

  Director, Infectious Diseases Fellowship and Education
  Division of Infectious Diseases, Houston Methodist Hospital
  Center of Excellence for Infectious Diseases Houston Methodist Research Institute
  Cleveland, Ohio, United States

  I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentations:

• Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
  

  Presenting Author: Joshua A. Hill, MD – Fred Hutchinson Cancer Research Center; University of Washington

  Co-Author: Roger Paredes, MD, PhD – Hospital Universitario Germans Trias i Pujol

  Co-Author: Carlos Vaca, MD – Nuren Medical and Research Center

  Co-Author: Jorge Mera, MD – Cherokee Nation Outpatient Health Center

  Co-Author: Brandon J. Webb, MD – Intermountain Healthcare

  Co-Author: Gilberto Perez, MD – Evolution Clinical Trials

  Co-Author: Godson Oguchi, MD – Midland Florida Clinical Research Center

  Co-Author: Pablo Ryan, MD PhD – Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid

  Co-Author: Jan Gerstoft, MD – University of Copenhagen

  Co-Author: Michael Brown, FRCP PhD – University College London Hospitals NHS Foundation Trust

  Co-Author: Joshua Schiffer, MD, MSc – Fred Hutch

  Co-Author: Samuel Brown, MD, MS – Intermountain Medical Center

  Co-Author: Morgan Katz, MD, MHS – Johns Hopkins University

  Co-Author: Adit A. Ginde, MD, MPH – University of Colorado

  Co-Author: Gregory Camus, PhD – Gilead Sciences, Inc

  Co-Author: Danielle P. Porter, PhD – Gilead Sciences, Inc.

  Co-Author: Robert H. Hyland, DPhil – AlloVir

  Co-Author: Shuguang Chen, PhD – Gilead Sciences, Inc

  Co-Author: Kavita Juneja, MD – Gilead

  Co-Author: Anu Osinusi, MD – Gilead

  Co-Author: Frank Duff, MD – Gilead Sciences, Inc

  Co-Author: Robert L. Gottlieb, MD – Baylor University Medical Center
• Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
  

  Presenting Author: Teresa H. Evering, MD – Weill Cornell Medicine

  Co-Author: Mark Giganti, Ph.D. – Harvard T.H. Chan School of Public Health

  Co-Author: Kara W. Chew, MD, MS – David Geffen School of Medicine at UCLA

  Co-Author: Michael Hughes, Ph.D. – Harvard T.H. Chan School of Public Health

  Co-Author: Carlee Moser, Ph.D. – Harvard T.H. Chan School of Public Health

  Co-Author: David Alain Wohl, MD – UNC School of Medicine

  Co-Author: Judith Currier, M.D., M.Sc. – David Geffen School of Medicine at University of California, Los Angeles

  Co-Author: Joseph J. Eron, MD – University of North Carolina at Chapel Hill

  Co-Author: Arzhang Javan, M.D., M.P.H., D.T.M&H – National Institute of Health

  Co-Author: David A. Margolis, MD MPH – Brii Biosciences

  Co-Author: Qing Zhu, PhD – Brii Biosciences

  Co-Author: Ulises D'Andrea, MD – Instituto Medico Rio Cuarto

  Co-Author: Keila Hoover, M.D. – Miami Clinical Research

  Co-Author: Bharat R. Mocherla, M.D. – Las Vegas Medical Research

  Co-Author: Courtney Fletcher, Pharm.D. – University of Nebraska

  Co-Author: Jonathan Li, M.D., M.M.Sc. – Brigham & Womens Hospital

  Co-Author: Davey Smith, M.D. – University of California, San Diego

  Co-Author: Eric Daar
• Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial
  

  Presenting Author: E. Wesley Ely, MD, MPH – Eli Lilly

  Co-Author: Athimalaipet V. Ramanan, FRCP – University of Bristol

  Co-Author: Cynthia E. Kartman, RN BSN – Eli Lilly and Company

  Co-Author: Stephanie de Bono, MD PhD – Eli Lilly and Company

  Co-Author: Ran Liao, PhD – Eli Lilly and Company

  Co-Author: Maria Lucia B Piruzeli, MD – Eli Lilly and Company

  Co-Author: Jason D. Goldman, MD, MPH – Swedish Medical Center, Seattle, WA, USA, and Division of Allergy and Infectious Diseases, University of Washington

  Co-Author: José Francisco Kerr Saraiva, MD PhD FACC FESC – IPECC - Instituto de Pesquisa Clínica de Campinas

  Co-Author: Sujatro Chakladar, PhD – Eli Lilly and Company

  Co-Author: Vincent Marconi, MD – Atlanta VA
• Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen
  

  Presenting Author: Eleftherios Mylonakis, MD, PhD – Brown University

  Co-Author: Selin Somersan-Karakaya, MD – Regeneron Pharmaceuticals Inc.

  Co-Author: Sumathi Sivapalasingam, MD – Regeneron Pharmaceuticals Inc

  Co-Author: Shazia Ali, PharmD – Regeneron Pharmaceuticals Inc.

  Co-Author: Yiping Sun, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Rafia Bhore, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Jingning Mei, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Jutta Miller, BS, RN – Regeneron Pharmaceuticals Inc.

  Co-Author: Lisa Cupelli, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Andrea T. Hooper, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Jennifer D. Hamilton, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Cynthia Pan, BPharm – Regeneron Pharmaceuticals Inc.

  Co-Author: Viet Pham, BS – Regeneron Pharmaceuticals Inc.

  Co-Author: Yuming Zhao, MS – Regeneron Pharmaceuticals Inc.

  Co-Author: Romana Hosain, MD, MPH – Regeneron Pharmaceuticals Inc.

  Co-Author: Adnan Mahmood, MD – Regeneron Pharmaceuticals Inc.

  Co-Author: John D. Davis, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Kenneth C. Turner, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Yunji Kim, PharmD – Regeneron Pharmaceuticals Inc.

  Co-Author: Amanda Cook, BS, Dip Reg Aff – Regeneron Pharmaceuticals Inc.

  Co-Author: Vidya Menon, MD – Lincoln Medical Center

  Co-Author: Jason C. Wells, MD – The Oregon Clinic

  Co-Author: Bari Kowal, MS – Regeneron Pharmaceuticals Inc.

  Co-Author: Yuhwen Soo, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: A. Thomas DiCioccio, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Gregory P. Geba, MD, DrPH – Regeneron Pharmaceuticals Inc.

  Co-Author: Neil Stahl, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Leah Lipsich, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: Ned Braunstein, MD – Regeneron Pharmaceuticals Inc.

  Co-Author: Gary Herman, MD – Regeneron Pharmaceuticals Inc.

  Co-Author: George D. Yancopoulos, MD, PhD – Regeneron Pharmaceuticals Inc.

  Co-Author: David M. Weinreich, MD – Regeneron Pharmaceuticals Inc.
• PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
  

  Presenting Author: Myron J. Levin, MD – University of Colorado Anschutz Medical Campus

  Co-Author: Andrew Ustianowski, MBBS – North Manchester General Hospital

  Co-Author: Stéphane De Wit, MD – CHU St-Pierre

  Co-Author: Odile Launay, MD, PhD – Université de Paris, Inserm F-CRIN I-REIVAC

  Co-Author: Miles Avila, MPH, GStat – AstraZeneca

  Co-Author: Seth Seegobin, PhD – AstraZeneca

  Co-Author: Alison Templeton, PhD – AstraZeneca

  Co-Author: Yuan Yuan, PhD – AstraZeneca, Gaithersburg, MD, USA

  Co-Author: Philip Ambery, FRCP – AstraZeneca

  Co-Author: Rosalinda H. Arends, PhD – AstraZeneca

  Co-Author: Rohini Beavon, PhD – AstraZeneca

  Co-Author: Karen A. Near, MD – AstraZeneca

  Co-Author: Kelly W. Padilla, PharmD – AstraZeneca

  Co-Author: Konstantina Psachoulia, PhD – AstraZeneca

  Co-Author: Audrey Sharbaugh, PhD – AstraZeneca

  Co-Author: Katie Streicher, PhD – AstraZeneca

  Co-Author: Menelas N. Pangalos, PhD – AstraZeneca

  Co-Author: Mark T. Esser, PhD – AstraZeneca

  Co-Author: Robert A. Gasser, Jr., MD – AstraZeneca